Cognitive disorders

Join the Race to End Alzheimer's by Featuring Your Loved One's Name On a Competitive Sports Car

Retrieved on: 
Saturday, July 17, 2021
Branches of biology, Cognitive disorders, Learning disabilities, Psychiatric diagnosis, Neuroscience, Psychiatry, Abnormal psychology, Alzheimer's disease, Dementia

The foundation has created a simple and meaningful process for people to support that "race" while also honoring their friends and family members.

Key Points: 
  • The foundation has created a simple and meaningful process for people to support that "race" while also honoring their friends and family members.
  • In 2017, Racing to End Alzheimer's began as a passion project for Frengs when his wife Mimi was diagnosed with early-onset Alzheimer's.
  • Frengs and the team behind Racing to End Alzheimer's have made the process of getting your loved one's name on a race car as easy as possible.
  • Learn more about Racing to End Alzheimer's or donate to remember your loved one on their website , r2endalz.org .

Caregiver Action Network Announces New Digital Tool for Caregivers of Loved Ones With Dementia

Retrieved on: 
Wednesday, July 14, 2021
Health, Human behavior, Psychiatric diagnosis, Caregiving, Aging-associated diseases, Cognitive disorders, Dementia, Caregiver, Family caregivers, Caring for people with dementia, Caregiver stress

Washington, DC, July 14, 2021 (GLOBE NEWSWIRE) -- Caregivers of loved ones with dementia are about to get more help thanks to Caregiver Action Network (CAN) .

Key Points: 
  • Washington, DC, July 14, 2021 (GLOBE NEWSWIRE) -- Caregivers of loved ones with dementia are about to get more help thanks to Caregiver Action Network (CAN) .
  • CAN is launching a new digital tool, Lighting Your Way: Dealing With the Behavioral Symptoms of Your Loved Ones Dementia , to help caregivers better understand some of the symptoms that can accompany dementia and what can be done about them.
  • Lighting Your Way: Dealing With the Behavioral Symptoms of Your Loved Ones Dementia provides information specifically tailored to family caregivers of those diagnosed with dementia in five sections.
  • For more details, please visit Lighting Your Way: Dealing With the Behavioral Symptoms of Your Loved Ones Dementia .

Assisted Living Locators National Team Gears Up For Walk To End Alzheimer's

Retrieved on: 
Thursday, July 15, 2021
Health, Branches of biology, Psychiatry, Cognitive disorders, Learning disabilities, Psychiatric diagnosis, Alzheimer's Association, Dementia, Assisted living, Alzheimer's disease

PHOENIX, July 15, 2021 /PRNewswire/ -- Assisted Living Locators, a National Team member of the Alzheimer's Association Walk to End Alzheimer's, is gearing up to support the world's largest event dedicated to Alzheimer's care, support and research.

Key Points: 
  • PHOENIX, July 15, 2021 /PRNewswire/ -- Assisted Living Locators, a National Team member of the Alzheimer's Association Walk to End Alzheimer's, is gearing up to support the world's largest event dedicated to Alzheimer's care, support and research.
  • "Assisted Living Locators is proud to support the Alzheimer's Association," said Angela Olea, Assisted Living Locators CEO RN.
  • Carolyn Marengere, Assisted Living Locators Metro Detroit franchisee and National Walk Team Coordinator, says it's exciting to have franchisees nationwide participating this year.
  • To join Assisted Living Locators' Walk to End Alzheimer's team, visit www.alz.org/assistedlivinglocators .If have questions about dementia care, speak to an Assisted Living Locators Senior Care Advisor at 877-266-7788 or visit www.assistedlivinglocators.com .

Cognito Therapeutics Announces Upcoming Data Presentations at the Alzheimer’s Association International Conference 2021

Retrieved on: 
Wednesday, July 14, 2021
Legal, Other Health, Technology, Pharmaceutical, Managed care, Professional services, Mental health, Hospitals, Clinical trials, Biotechnology, Science, Software, Other Science, Nursing, Research, Health, Branches of biology, Psychiatry, Biology, Cognitive disorders, Learning disabilities, Psychiatric diagnosis, Behavior modification, Digital therapeutics, Dementia, Alzheimer's disease, Neurodegeneration

Cognito Therapeutics , a clinical-stage company developing a new class of disease-modifying digital therapeutics targeting neuronal pathophysiology to treat neurodegenerative disorders, today announced the acceptance of six research abstracts at the Alzheimers Association International Conference 2021 (AAIC) .

Key Points: 
  • Cognito Therapeutics , a clinical-stage company developing a new class of disease-modifying digital therapeutics targeting neuronal pathophysiology to treat neurodegenerative disorders, today announced the acceptance of six research abstracts at the Alzheimers Association International Conference 2021 (AAIC) .
  • The largest international meeting dedicated to advancing dementia science, AAIC will be held as an online and in-person event in Denver, Colorado, July 26-30, 2021.
  • Our clinical team continues to produce compelling patient data of both physiological and symptomatic improvements that support disease modification for our lead digital therapeutic development program in mild cognitive impairment (MCI) and Alzheimers Disease, said Brent Vaughan, Chief Executive Officer, Cognito Therapeutics.
  • Cognito Therapeutics is a clinical-stage company developing a pipeline of disease-modifying digital therapeutics targeting neurodegenerative disorders.

Initial Launch Execution Fails to Impress for Biogen's Aduhelm - the First-to-Market Disease-Modifying Therapy for the Treatment of Alzheimer's Disease - as the Controversy Churn Continues, According to Spherix Global Insights

Retrieved on: 
Wednesday, July 14, 2021
Life sciences, Branches of biology, Biology, Monoclonal antibodies, Biogen, Spinal muscular atrophy, Cognitive disorders, Benchmarking, Neurology, Aducanumab, Alzheimer's disease

Spherix initiated their Launch Dynamix: Aduhelm (Biogen) in Alzheimer's Disease (US) service immediately upon approval to provide clients with an ongoing, real-time assessment of the brand's launch and to capture vital benchmarking for potential future launches.

Key Points: 
  • Spherix initiated their Launch Dynamix: Aduhelm (Biogen) in Alzheimer's Disease (US) service immediately upon approval to provide clients with an ongoing, real-time assessment of the brand's launch and to capture vital benchmarking for potential future launches.
  • Surveyed neurologists anticipate that only one in seven Alzheimer's patients are considered candidates for Aduhelm.
  • Biogen, considered a powerhouse in the multiple sclerosis market, has not yet fueled comparable loyalty in the Alzheimer's market.
  • All company, brand or product names in this document are trademarks of their respective holders.

Memory Health Awarded Supplement Certified Seal Of Approval For Quality And Stability

Retrieved on: 
Tuesday, July 13, 2021
Branches of biology, Mind, Cognitive disorders, Neuroscience, Senescence, Dementia, Dietary supplement, Neurodegeneration, Memory

BIRMINGHAM, Mich., July 13, 2021 /PRNewswire/ -- Memory Health, the only supplement patented for the prevention and/or treatment of neurodegenerative disease, today announced it has been awarded the "Supplement Certified" ( https://www.supplementcertified.ie) seal of approval by the Nutrition Research Centre of Ireland (NRCI), Waterford Institute of Technology (WIT).

Key Points: 
  • BIRMINGHAM, Mich., July 13, 2021 /PRNewswire/ -- Memory Health, the only supplement patented for the prevention and/or treatment of neurodegenerative disease, today announced it has been awarded the "Supplement Certified" ( https://www.supplementcertified.ie) seal of approval by the Nutrition Research Centre of Ireland (NRCI), Waterford Institute of Technology (WIT).
  • This means that even with a healthy diet, supplementation is now necessary to protect our brain health," said Edward Shehab, co-founder and managing partner, Memory Health.
  • "Our food and several other brain health supplement manufacturers have failed us; however, Memory Health has taken this extra step of certification to assure individuals who understand and seek to improve their brain health are getting what Memory Health has promised them at every step of their wellness journey."
  • Memory Health is the first supplement to receive a United States patent for theprevention and/or treatment of neurodegenerative disease, especially dementia, in human subjects.

Ensuring Timely, Appropriate And Equitable Access To Aduhelm

Retrieved on: 
Sunday, July 11, 2021
Psychiatry, Cognitive disorders, Learning disabilities, Psychiatric diagnosis, Branches of biology, Neuroscience, Alzheimer's disease, Dementia, Aducanumab, Mild cognitive impairment, Alzheimer's Association

CHICAGO, July 11, 2021 /PRNewswire/ --Aduhelm has been approved for use for those with Mild Cognitive Impairment or early stage Alzheimer's dementia.

Key Points: 
  • CHICAGO, July 11, 2021 /PRNewswire/ --Aduhelm has been approved for use for those with Mild Cognitive Impairment or early stage Alzheimer's dementia.
  • Though approved, access to the treatment is at risk of being impeded by significant barriers which may further deepen issues of health equity.
  • From the Association's very first comment on aducanumab, we have stressed the importance of post-approval surveillance through a confirmatory trial.
  • The Alzheimer's Association is committed to working with CMS and the private payer community to expedite access for the appropriate population, which has such significant need.

Muna Therapeutics Launches with US$ 73M Series A to Advance Novel Small Molecule Therapeutics for Neurodegenerative Diseases

Retrieved on: 
Friday, July 9, 2021
Branches of biology, Cognitive disorders, Psychiatry, Psychiatric diagnosis, Neuroscience, Dementia, Aging-associated diseases, Neurological disorders, Neurodegeneration, Frontotemporal dementia

Muna is focused on addressing the staggering unmet need experienced by patients around the world with neurodegenerative disorders.

Key Points: 
  • Muna is focused on addressing the staggering unmet need experienced by patients around the world with neurodegenerative disorders.
  • Muna has built a cutting-edge small molecule drug discovery engine that leverages high-resolution target structural approaches, AI-driven computational chemistry and cell-based screening.
  • "Our team is committed to leveraging our collective expertise to deliver impactful disease modifying small molecule therapeutics to patients as rapidly as possible."
  • Muna discovers and develops therapies that slow or stop devastating neurodegenerative diseases including Alzheimer's, Frontotemporal Dementia and Parkinson's.

Alzheimer's Association Welcomes Revised Label For Aduhelm

Retrieved on: 
Thursday, July 8, 2021
Psychiatry, Branches of biology, Cognitive disorders, Learning disabilities, Psychiatric diagnosis, Alzheimer's disease, Neuroscience, Monoclonal antibodies, Aducanumab, Alzheimer's Association, Dementia

CHICAGO, July 8, 2021 /PRNewswire/ --The Alzheimer's Association is pleased with the announcement today that the Food and Drug Administration (FDA) has revised the prescribing label for Aduhelm (aducanumab).

Key Points: 
  • CHICAGO, July 8, 2021 /PRNewswire/ --The Alzheimer's Association is pleased with the announcement today that the Food and Drug Administration (FDA) has revised the prescribing label for Aduhelm (aducanumab).
  • "Today's announcement is consistent with the Alzheimer's Association position that Aduhelm should be made available specifically to the population represented in the clinical trials where there was evidence of clinical benefit," said Maria C. Carrillo, Ph.D., Alzheimer's Association chief science officer.
  • The Alzheimer's Association is committed to working with the Centers for Medicare & Medicaid Services (CMS) and the private payer community to expedite access for the appropriate population, which has such significant need.
  • The Alzheimer's Association leads the way to end Alzheimer's and all other dementia by accelerating global research, driving risk reduction and early detection, and maximizing quality care and support.

Belmont Village Senior Living Shares Key Neuroscience Insights into Better Understanding the Alzheimer’s Brain from Yale University’s Dr. Stephen Strittmatter

Retrieved on: 
Thursday, July 8, 2021
Research, Nursing, Seniors, Other Health, Managed care, Health, Consumer, General Health, Science, Branches of biology, Clinical medicine, Medicine, Cognitive disorders, Learning disabilities, Psychiatric diagnosis, Strittmatter, Alzheimer's disease, Belmont, Sjögren syndrome

Belmont Village Senior Living was honored to sponsor an incredibly rich & important discussion with the brilliant Dr. Strittmatter, says Patricia Will, founder and CEO of Belmont Village.

Key Points: 
  • Belmont Village Senior Living was honored to sponsor an incredibly rich & important discussion with the brilliant Dr. Strittmatter, says Patricia Will, founder and CEO of Belmont Village.
  • At Belmont Village, we know everyone experiences memory loss differently, so learning details of how it occurs is essential to executing proper memory preservation therapy techniques and activities.
  • Dr. Strittmatter mentioned that while there are medications approved to provide slight symptomatic benefit, there is still no cure for Alzheimers.
  • The plaques, and the cells causing the biochemical reaction, are key factors in identifying Alzheimers in the brain.